Skip to main content
. Author manuscript; available in PMC: 2023 Jan 5.
Published in final edited form as: Clin Cancer Res. 2022 Mar 1;28(5):860–869. doi: 10.1158/1078-0432.CCR-21-1090

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Overall survival (A), radiographic progression-free survival (B), and PSA progression-free survival (C), with and without baseline corticosteroid use.

CI, confidence interval; HR, hazard ratio (enzalutamide vs. placebo); NR, not reached; OS, overall survival; PSA, prostate-specific antigen; rPFS, radiographic progression-free survival; TTPP, time to PSA progression.